Description
The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing.
With the changing market landscape, BioCDMOs are shifting toward providing value-added services by establishing themselves as a one-stop-shop for their pharma clients. These companies are adopting advanced manufacturing technologies such as single-use/disposable bioreactors, continuous, POD manufacturing, and so on with the integration of IT-based solutions implementing the Industrial Internet of Things (IIoT) by means of strategic collaborations and partnerships. Larger participants are resorting to Mergers and Acquisitions (M&As) in order to gain specific therapeutic and technical expertise from smaller, niche BioCDMOs. While the US and Europe are key markets, the outsourcing trend is slowly shifting toward APAC with several new entrants providing cost-effective drug development services.
Don't have an account? Create One!
Already have an account? Login!
Connect With LinkedIn
Use your Linkedin account to login or register within our store.You're just one click away.